You split a 10mg THC gummy with a friend. Same product, same dose, same evening. Two hours later, you feel a pleasant, manageable buzz. Your friend is on the couch questioning their life decisions. This is not an unusual cannabis experience — it is, in fact, the norm. And for years, the explanation has been frustratingly vague: body weight, tolerance, what you ate, your metabolism. “Everyone’s different.”
A research team at the University of Colorado may have just found one of the most specific and testable reasons why: your blood type.
The Enzyme That Decides Your Edible Experience
To understand why blood type might matter for edibles, you first need to understand what happens to THC after you swallow it — because the journey from gummy to high is far more complex than inhaling smoke.
When you smoke or vape cannabis, THC enters the bloodstream through the lungs and reaches the brain within seconds. The THC molecule (delta-9-THC) itself is the primary psychoactive agent, and the onset is fast, peaking within 10 to 30 minutes.
Edibles take a fundamentally different route. THC is absorbed through the gastrointestinal tract, passes through the intestinal wall, and enters the hepatic portal vein, which delivers it directly to the liver. This is called first-pass metabolism, and it changes the game entirely.
In the liver, an enzyme called CYP2C9 converts delta-9-THC into 11-hydroxy-THC (11-OH-THC). This metabolite is not a waste product — it is psychoactive, and by most measures, significantly more potent than delta-9-THC itself. 11-OH-THC crosses the blood-brain barrier more efficiently and binds to CB1 receptors with greater affinity. This is why edibles produce a qualitatively different high than smoking: it is literally a different molecule doing most of the work.
The speed at which your liver performs this conversion — how fast CYP2C9 does its job — determines nearly everything about your edible experience. How quickly the effects come on, how intense they become, and how long they last.
Enter CYP2C9: The Gene That Varies Wildly
CYP2C9 is part of the cytochrome P450 superfamily, a collection of enzymes responsible for metabolizing an enormous proportion of pharmaceutical drugs. CYP2C9 specifically handles warfarin (a blood thinner), many NSAIDs, some antidiabetic drugs, and — as researchers increasingly recognize — THC.
Here is what makes CYP2C9 particularly interesting: it is one of the most polymorphic drug-metabolizing enzymes in humans. Over 60 variant alleles have been identified, and the differences between them are not subtle. Some variants metabolize substrates at normal speed (these are called “extensive metabolizers”). Others operate at dramatically reduced capacity (“poor metabolizers”). And the distribution of these variants differs significantly across ethnic and genetic populations.
The three most studied variants are CYP2C91 (the “wild type” or normal version), CYP2C92, and CYP2C9*3. Individuals who carry two copies of the *1 allele are normal metabolizers. Those with one or two copies of *2 or *3 are intermediate or poor metabolizers. The *3 variant is particularly impactful — a homozygous *3/*3 individual may metabolize certain substrates at only 5 to 10 percent of the normal rate.
This is well-established pharmacogenomics, and it already influences clinical medicine. Doctors routinely test for CYP2C9 variants before prescribing warfarin because the dosing difference between a normal and poor metabolizer can be the difference between therapeutic anticoagulation and a dangerous bleeding event.
What the University of Colorado team has added to this picture is a proposed mechanism linking ABO blood type to CYP2C9 expression levels and activity — a connection that, if validated, would provide the most accessible biomarker yet for predicting edible cannabis response.
The University of Colorado Study
The research, conducted by a team in the Department of Pharmaceutical Sciences and published in early 2026, examined 312 regular cannabis consumers who were given standardized oral THC doses under controlled laboratory conditions. Participants received 10mg of THC in an edible form, and researchers tracked plasma concentrations of both delta-9-THC and 11-OH-THC at intervals over eight hours. Participants were also genotyped for CYP2C9 variants and had their ABO blood type determined.
The findings revealed a statistically significant association between ABO blood type and the rate of THC-to-11-OH-THC conversion.
Type O participants showed the fastest median conversion rates, with peak 11-OH-THC concentrations occurring at a median of 45 minutes post-ingestion. Their peak plasma levels of 11-OH-THC were approximately 40 percent higher than Type A participants on a per-milligram basis.
Type A participants showed the slowest median conversion, with peak 11-OH-THC concentrations not occurring until a median of 90 minutes post-ingestion. Their peak levels were lower but more sustained, with detectible 11-OH-THC remaining in plasma significantly longer than in Type O participants.
Type B participants fell between O and A in most measures, with a median peak at approximately 65 minutes.
Type AB participants showed the most variable results, which the researchers attributed to the heterozygous nature of the AB phenotype and the smaller sample size for this blood type (AB is the rarest, occurring in roughly 4 percent of the population).
The proposed mechanism centers on the ABO gene’s influence on glycosyltransferase enzymes, which modify proteins throughout the body — including, the researchers hypothesize, the post-translational modification of CYP2C9 enzyme in hepatocytes. Different ABO alleles produce different glycosylation patterns, which may affect enzyme folding, stability, and catalytic efficiency.
What This Means in Practical Terms
If the Colorado findings hold up under replication, the implications for cannabis consumers are significant and immediately practical.
For Type O individuals: The fast-metabolizer profile means edibles hit harder and sooner. A 10mg dose may feel more like a 14mg dose experienced by a Type A individual, and the onset window is compressed. The good news is that the effects may also clear faster. The risk is overconsumption during the onset period — the “I don’t feel anything yet, better take another” trap is particularly dangerous for fast metabolizers because the second dose kicks in just as the first one peaks.
For Type A individuals: The slow-metabolizer profile means patience is essential. A 10mg dose may take 90 minutes to two hours to reach full effect, and the peak may be lower but considerably longer-lasting. Type A individuals may find that edibles produce a more gradual, extended experience. The risk here is a different kind of overconsumption: the long delay to onset can lead to redosing, and because the metabolite clears slowly, the second dose stacks on top of the first in a way that can produce unexpectedly intense effects hours later.
For Type B individuals: The intermediate profile suggests a relatively standard edible experience, with onset in the 60-to-90-minute range and moderate peak intensity.
For Type AB individuals: The high variability observed in the study means that Type AB individuals may have the least predictable edible experiences. Some may metabolize like Type A, others like Type O, and some may show mixed patterns that vary between sessions.
The Pharmacogenomics Context
The Colorado study does not exist in a vacuum. It builds on decades of pharmacogenomic research demonstrating that genetic variation in drug-metabolizing enzymes produces clinically meaningful differences in drug response.
The most well-established example involves codeine, a prodrug that must be converted by the CYP2D6 enzyme into morphine to produce pain relief. Approximately 6 to 10 percent of Caucasian populations are CYP2D6 poor metabolizers, meaning codeine is essentially ineffective for them. Conversely, 1 to 2 percent are “ultrarapid metabolizers” who convert codeine to morphine so efficiently that standard doses can produce dangerous respiratory depression. This is not theoretical — it has caused deaths, particularly in children, and has led to FDA black box warnings.
The parallel to THC metabolism is direct. If CYP2C9 polymorphisms produce a similar spectrum of metabolizer phenotypes for THC — and the existing data strongly suggests they do — then the difference between a person who processes 10mg of THC normally and one who processes it at 40 percent higher efficiency is not trivial. It is the difference between a pleasant evening and a panic attack.
What the blood type connection adds is a potential screening shortcut. CYP2C9 genotyping requires a DNA test — not expensive (typically $100 to $300 for a clinical pharmacogenomic panel), but not something most cannabis consumers are going to pursue. Blood type, by contrast, is information that most people already know. If blood type reliably predicts CYP2C9 activity for THC metabolism specifically, it becomes an accessible heuristic for personalized dosing.
Why 10mg Hits Everyone Differently
The standard “dose” in regulated cannabis markets is 10mg of THC. This number was essentially chosen by Colorado regulators when the state launched adult-use sales in 2014, and it has since been adopted as the default serving size across most legal markets. But the 10mg standard dose is a regulatory convenience, not a pharmacological truth.
For a 200-pound male with Type O blood and normal CYP2C9 activity, 10mg may produce a moderate, manageable effect. For a 120-pound female with Type A blood and a CYP2C9*3 variant, that same 10mg may produce an overwhelming experience that lasts six to eight hours.
The variables that influence edible response include, at minimum: body weight and body composition (THC is lipophilic and distributes into fat tissue), recent food intake and composition (fat content of a meal significantly affects THC absorption), CYP2C9 genotype, liver function, prior cannabis tolerance, concurrent medications that compete for CYP2C9 metabolism, gut microbiome composition (emerging research), and — if the Colorado study is validated — ABO blood type as a proxy for CYP2C9 expression patterns.
The 10mg standard dose attempts to find a middle ground that works for most people, but the biological reality is that there is no single dose that produces a consistent experience across the population. This is why “start low, go slow” remains the most important advice for edible consumers, and why the Colorado research, if replicated, could move the industry toward more sophisticated dosing guidelines.
The Future of Personalized Dosing
The cannabis industry has been moving toward personalized products for years, but mostly in superficial ways — strain-specific edibles, terpene-enhanced formulations, products marketed for “relaxation” versus “energy.” These distinctions are largely based on terpene profiles and cannabinoid ratios, which do influence the subjective experience but do not address the fundamental metabolic variability that determines how much active compound actually reaches your brain.
Pharmacogenomic dosing would represent a qualitative leap in personalization. Imagine a dispensary consultation that begins with two questions: What is your blood type? Have you had a pharmacogenomic panel? Based on the answers, the budtender could recommend not just a product but a specific starting dose calibrated to the consumer’s likely metabolic profile.
Some companies are already moving in this direction. Pharmacogenomic testing services marketed to cannabis consumers have emerged, though their scientific foundations vary in rigor. The Colorado study, if replicated, could provide the clinical evidence needed to legitimize these services and integrate them into standard dispensary practice.
The regulatory implications are also significant. If blood type or CYP2C9 genotype reliably predicts edible sensitivity, regulators might consider requiring dosing guidance on product labels that acknowledges metabolic variability — much as pharmaceutical products include dosing adjustments for renal or hepatic impairment.
Limitations and Caveats
It is important to note what the Colorado study does not prove. The association between blood type and THC metabolism, while statistically significant, requires independent replication before it can be considered established. A single study with 312 participants, while well-designed, is not sufficient to change clinical practice or consumer guidance.
Several specific limitations merit attention.
Sample demographics: The study population was predominantly white and of European descent, reflecting the demographics of the Colorado cannabis consumer base. CYP2C9 variant frequencies differ significantly across ethnic populations — the *2 and *3 alleles are most common in European populations, while other variants predominate in Asian and African populations. The blood type association may not hold across all genetic backgrounds.
Confounding variables: Despite the controlled laboratory setting, numerous variables that influence edible metabolism — recent diet, concurrent medications, liver health, gut microbiome — could not be fully controlled or accounted for. The researchers used statistical methods to adjust for known confounders, but unknown confounders may exist.
Mechanism uncertainty: The proposed mechanism — ABO glycosyltransferase influence on CYP2C9 post-translational modification — is plausible but not directly demonstrated by this study. The researchers observed a correlation between blood type and metabolic rate but did not directly measure the enzymatic mechanism. Future studies using liver cell cultures or animal models will be needed to establish the mechanistic pathway.
Effect size: While a 40 percent difference in peak 11-OH-THC concentration between Type O and Type A is meaningful, individual variation within each blood type group was substantial. Blood type is likely one factor among many, not a sole determinant. A Type A individual with other genetic or physiological characteristics favoring fast metabolism might still process edibles quickly.
What Consumers Should Do With This Information
Until the blood type association is replicated and refined, it should be treated as one data point among many — interesting and potentially useful, but not definitive.
That said, if you know your blood type, it may be worth considering alongside other factors when calibrating your edible dose.
If you are Type O, you may want to start with a lower dose than the standard 10mg — perhaps 5mg — and wait at least 90 minutes before considering a second dose, even if the effects seem mild at 45 minutes. Your fast metabolism means the peak will come sooner and potentially stronger than you expect.
If you are Type A, patience is your best strategy. Start with a standard dose, but commit to waiting at least two full hours before concluding that you need more. Your metabolic profile suggests a slower, more gradual onset, and redosing before the first dose has peaked is the most common cause of unpleasant edible experiences.
If you are Type B or AB, the general “start low, go slow” guidance applies. Type AB individuals in particular should approach edibles with extra caution given the high variability observed in the study.
For everyone, regardless of blood type, the most important variables remain the basics: your prior cannabis experience, what you have eaten recently, whether you are taking medications that compete for CYP2C9 metabolism, and your overall physical and mental state. Blood type may add a useful layer of personalization to edible dosing, but it does not replace the fundamental principles of responsible consumption.
The era of pharmacogenomic cannabis is coming. It may not arrive as a blood test at the dispensary counter next year, but the trajectory is clear. The same precision medicine revolution that has transformed oncology, cardiology, and pain management is beginning to reach cannabis — and the day when your edible dose is calibrated to your genome, not a regulatory average, is closer than most consumers realize.